Atricure, Inc. ( (ATRC) ) has released its Q4 earnings. Here is a breakdown of the information Atricure, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AtriCure, Inc. is a leading medical device company specializing in innovative surgical treatments for atrial fibrillation and related conditions, including left atrial appendage management and post-operative pain management.
In its latest earnings report, AtriCure announced a robust performance for the fourth quarter and full year of 2024, with significant growth in revenue driven by new product launches and increased market penetration.
For the fourth quarter of 2024, AtriCure reported a worldwide revenue of $124.3 million, marking a 16.6% year-over-year increase. The company launched several new devices in the U.S. and Europe, contributing to the overall growth. Full-year revenue reached $465.3 million, a 16.5% increase over the previous year. Despite an increase in gross profit, the company recorded a net loss due to higher research and development expenses, including a $12 million acquisition cost for in-process research and development.
The company’s adjusted EBITDA showed positive growth, with $12.7 million for the fourth quarter and $31.1 million for the full year 2024. AtriCure’s strategic focus on product innovation and market expansion has been a key driver of its financial performance.
Looking ahead to 2025, AtriCure projects continued revenue growth, estimating a range of $517 million to $527 million. The management anticipates further improvements in adjusted EBITDA and expects modest cash flow generation throughout the year, indicating a positive outlook for the company’s financial health and strategic initiatives.
